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10 years of Cell Death & Disease
Mauro Piacentini1,2, Yufang Shi3,4 and Hans-Uwe Simon 5,6
Cell Death & Disease is celebrating its 10th anniversary.
In the last 10 years from its foundation the content of Cell
Death & Disease has covered an enormous breadth of
subjects at the forefront of experimental medicine and
clinical practice. The Journal’s mission aims to encompass
the breadth of translational implications of cell death in
the pathogenesis of major human diseases. To mark this
important milestone, we requested updates of the
research of those scientists who have significantly con-
tributed in this decade to the activity of the Journal with
highly cited publications. These high influential original
papers together with topical reviews have led Cell Death
& Disease to become a successful landmark in science
publishing as highlighted by its growing altmetrics and
high impact factor (2019 IF 6.3). The central purpose of
Cell Death & Disease is the publication of original peer-
reviewed work that constitutes the true basis for advan-
cing biomedical science. This commemorating review set
includes four reviews dealing with hot aspects of cancer
such as the role cell death regulators, exosomes, meta-
bolism, and long non-coding RNAs and their possible
implications in therapy1–4. The fifth contribution
encompasses the recent developments in the field of
metabolic diseases such as non-alcoholic fatty liver dis-
ease (NAFLD), the most common cause of chronic liver
disease worldwide5. One of the major translational
achievement of the cell death field is the development of
BCL-2 family protein inhibitors such as Venetoclax (ABT-
199, GDC-0199), the first clinically approved drug of this
class, which is currently used in the treatment of chronic
lymphocytic leukemia (CLL) as well as acute myeloid
leukemia (AML)6. However, despite remarkable clinical
results, a prolonged treatment with the Venetoclax
monotherapy leads to drug resistance. The review by
Kapoor et al.1 analyzes in detail the mechanism of action
of BCL-2 inhibition focusing on the acquired resistance to
venetoclax as well as on the possibility that tumors initi-
ally resistant to Venetoclax become responsive to it fol-
lowing prior therapies. In the last few years, we have also
witnessed another revolution in cancer treatment through
targeting the tumor microenvironment to enhance the
antitumor immunity. The cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed death
1 (PD-1) immune checkpoints are negative regulators of
T-cell immune function and their inhibition resulting in
increased activation of the immune system is the new
frontiers in cancer treatment6. However, many cancer
patients do not respond initially or develop secondary
resistance. In their review, Cerezo and Rocchi2 discuss
how targeting metabolism could help modulate antitumor
immunity and exploring the possibility that the metabolic
reprogramming in cancer cells may represent a way to
favor the antitumor response7. Another key factor in the
development of cancer tumor resistance to therapy is
discussed in the review by Dong et al.3 highlighting the
contribution of exosomes to drug resistance in breast
cancer. The authors dissect out the role of exosomes
biogenesis, the influence of their cargos, and the pattern
of release in response to drug treatment. In particular,
they discuss how proteins or non-coding RNAs contained
in exosomes released in the tumor microenvironment by
the tumor itself and/or the stromal cells are able to
influence drug resistance by altering the metabolism, pro-
survival signaling, epithelial-mesenchymal transition,
stem-like property of breast cancer. Breast cancer
metastasis is the major cause of mortality in female
patients8. An increasing number of studies published in
Cell Death & Disease focus on the involvement of long
non-coding RNAs (lncRNAs) in cancer metastasis; how-
ever, a defined role of these lncRNAs are yet to be clar-
ified9–11. The review by Liu et al.4 focuses on the lncRNAs
functions in breast cancer invasion and metastasis, with
particular emphasis on their dual functions for metastasis,
their functional mechanisms, their regulatory factors, and
the therapeutic promises. The last review by Rada et al.5
of this collection does not appear to be related to the
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previous ones at a first glance. Indeed it discusses a
metabolic aspect that is assuming more and more
importance nowadays. In fact, non-alcoholic fatty liver
disease (NAFLD) is the commonest cause of chronic liver
disease world-wide and can progress to cirrhosis and
hepatocellular carcinoma12. The global prevalence of
NAFLD is thought to be constantly increasing, being
currently estimated to about 25% of the population13. The
review by Rada et al. discuss some of the molecular
mechanisms that can be responsible for lipotoxicity in
NAFLD, including ER and oxidative stress, autophagy,
lipoapoptosis, and inflammation. In particular, the review
highlights the role of CD36/FAT fatty acid translocase in
NAFLD pathogenesis. Clinical studies have shown that
CD36 increased levels in the liver of NAFLD patients as
well as circulating levels of a soluble form of CD36
(sCD36) that are positively correlated with the histological
grade of hepatic steatosis. The authors highlight how
CD36 or some of its functional regulators may be a pro-
mising therapeutic approach for the prevention and
treatment of NAFLD and consequently of cirrhosis and
hepatocellular carcinoma. We hope that the readers enjoy
this review set which represents just the tip of the iceberg
of our past, present, and future commitment to advance
translational science. The Cell Death & Disease foremost
goal is to publish a peer-reviewed scientific journal of the
highest quality focused on understanding the mechanistic
bases of disease. If we achieve this goal, the merit goes to
the authors who have contributed their original work to
our Journal and to the Editors and Reviewers who pro-
vided the expertise for processing the thousand manu-
scripts we annually receive. We finally would like to thank
all the past and present members of our Editorial Office as
well as the hard-working production Editors at Springer/
Nature, as they finalize the publication of the high-quality
papers to which we became accustomed.
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